LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

GE HealthCare to Host its 2024 Investor Day on November 21

November 07, 2024 | Last Trade: US$81.45 2.34 -2.79

CHICAGO / Nov 07, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) will host its Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY, where its management team will present its growth strategies, technology portfolio, and vision for its businesses. A technology showcase will follow the presentations for in-person attendees. Registration is required.

The live webcast will be available at https://investor.gehealthcare.com/news-events/events.The press release, presentation, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page